Research-grade compound. Laboratory use only. Not intended for human or animal use, ingestion, or injection. No medical claims are made or implied.
BPC-157
This report covers the 20mg lot. Other sizes ship to our supplier batch specification.
3–7 days most of the EU · 8–14 Nordics/Baltics
Standard EU from €4.99 (RO) · core EU GLS €17.99 · Nordics/Baltics €12.99–€13.99 · Same-day dispatch before 14:00 CET on weekdays · Free shipping over €200 · no customs paperwork (EU) · via EU carrier network
€200.00 away from free shipping over €200. Under that, standard EU shipping is €17.99 (GLS, most of the EU).
How Paysera and SEPA work
- Pay — approve a SEPA transfer in your own bank via Paysera’s hosted page, or send a manual SEPA transfer using the IBAN we email you.
- We confirm — Paysera notifies us instantly, or we match a manual transfer when it arrives (usually 1 business day).
- We dispatch — confirmed orders placed before 14:00 CET on a weekday typically ship the same day.
Card payments are not currently offered. There is no card processor on this checkout.
Free shipping on orders over €200
BPC-157 (Body Protection Compound 157) is a stable 15-amino-acid pentadecapeptide fragment derived from a gastric juice protein, supplied by CertaPeptides as a lyophilized laboratory research compound (≥98% supplier batch specification; CAS 137525-51-0). In preclinical literature, Sikiric et al. (2014, PMID 23755725) reported effects on the nitric oxide system in rodent models, and Chang et al. (2014, PMID 25415472) observed increased growth hormone receptor expression in cultured tendon fibroblasts. These findings are reported here for research context only and are not medical claims. For laboratory research use only. Not for human consumption.
| Quantity | Price Each | Total | Savings |
|---|---|---|---|
| 1 unit | €19.99 | €19.99 | -- |
| 3+ | €18.99 | €56.97 | 5% off |
| 5+Most Popular | €17.99 | €89.96 | 10% off |
| 10+ | €16.99 | €169.92 | 15% off |
Important Notice
This product is intended for laboratory and research use only. Not for human or veterinary use. By purchasing, you confirm this product will be used exclusively for in-vitro research purposes.
Reconstitution Required
This peptide ships lyophilized (dry powder) and requires bacteriostatic water to reconstitute before use. BAC water is sold separately.
Recommended: BAC water · stable for 28 days at 2-8°C once mixed.
When This Product May Not Suit Your Research
- ⚠If your research requires oral bioavailability data — BPC-157's oral pharmacokinetics in humans remain under-investigated.
- ⚠If you need GMP-grade material for clinical applications — research-grade peptides are not suitable for clinical use.
- ⚠If your study protocol requires FDA-approved compounds — BPC-157 is not FDA-approved for any therapeutic use.
Published laboratory reports are available for selected lots. Check each report for its result and stated method. For research purposes only.
This report covers the 20mg lot. Other sizes ship to our supplier batch specification.
24h dispatch, EU-wide shipping from €4.99
Supplier batch specification on every product; independent Janoshik report on selected lots
About BPC-157
What Is BPC-157?
BPC-157 ("Body Protection Compound 157") is a synthetic pentadecapeptide — a 15-amino-acid sequence originally isolated as a fragment of a protein found in gastric juice. It is supplied by CertaPeptides as a pharmaceutical-grade lyophilized powder for in vitro and preclinical research use.
CAS: 137525-51-0. Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
What Published Research Has Reported
The statements below are direct attributions to peer-reviewed preclinical studies. They describe observations in animal models or in vitro systems only and should not be interpreted as human clinical claims.
- Sikiric et al. (2014) reviewed the role of the nitric oxide system in rodent BPC-157 studies and reported interactions between the pentadecapeptide and NO-pathway modulators in gastrointestinal and vascular experimental models. Source: Current Pharmaceutical Design, 20(7), 1126–1135. PMID 23755725.
- Chang et al. (2014) reported that, in cultured rat Achilles tendon fibroblasts, BPC-157 exposure was associated with increased growth hormone receptor expression compared to control. Source: Molecules, 19(11), 19066–19077. PMID 25415472.
- Krivic et al. (2008) observed, in a rat Achilles tendon-to-bone transection model, differences in early functional recovery measurements between BPC-157-treated animals and controls. Source: Inflammation Research, 57(5), 205–210. PMID 18594781.
- Staresinic et al. (2006) reported outcome measurements after application of BPC-157 in a rat transected-quadriceps model. Source: Journal of Orthopaedic Research, 24(5), 1109–1117. PMID 16609979.
Research Areas Where BPC-157 Is Studied
- Preclinical models of musculoskeletal tissue response (rodent tendon, ligament, muscle)
- In vitro fibroblast and endothelial cell culture assays
- Experimental gastrointestinal mucosa models in rats and mice
- Nitric-oxide pathway signalling studies in animal tissue
Within the Tissue-Repair Cluster — How BPC-157 Differs
BPC-157 is studied alongside two other research peptides in overlapping tissue-repair contexts: TB-500 (a 17-amino-acid fragment of thymosin β-4) and the combined BPC-157 + TB-500 blend. These compounds come from different biological origins and modulate different molecular pathways, which is why researchers often use them in combination rather than as substitutes:
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Biological origin | Fragment of a protein found in gastric juice (BPRP) | Active fragment (aa 17–23) of thymosin β-4, found in most mammalian cells |
| Amino acid length | 15 (pentadecapeptide) | 17 (heptadecapeptide) |
| Molecular weight | 1419.53 Da | 4963.5 Da |
| Primary mechanism studied | Nitric-oxide pathway, VEGFR2/angiogenesis, mucosal protection | Actin sequestration, cell migration, cytoskeletal dynamics |
| Best-characterised preclinical models | Rodent GI mucosa; Achilles/quadriceps transection; vascular NO assays | Cardiac epicardial progenitor; corneal inflammation; wound migration |
| Oral-route research context | Studied in oral delivery; shows gastric stability | Primarily injectable research; limited oral data |
BPC-157's distinguishing research angle is its gastric origin and mucosal-protection phenotype: it is the only compound in this cluster with published preclinical evidence in GI mucosa models, and the only one routinely studied under oral administration. For researchers investigating combined actin-cytoskeletal + nitric-oxide pathways in the same protocol, the BPC-157 + TB-500 blend presents a fixed 1:1 formulation; for independent dose control or single-pathway studies, the individual products are preferred. Researchers comparing the two frequently reference the TB-500 vs BPC-157 comparison, the blend-vs-individual decision guide, and the ultimate guide to BPC-157 research.
Specifications
| CAS Number | 137525-51-0 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.53 g/mol |
| Purity | ≥98% (supplier batch spec) |
| Physical Form | Lyophilized (freeze-dried) powder |
| Salt form | Acetate (standard BPC-157, not arginate/PDA) |
| Available Sizes | 2mg, 5mg, 10mg, 20mg |
Storage
Lyophilized: −20°C for long-term storage (2+ years stable). 2–8°C for short-term use.
Reconstituted: 2–8°C, use within 4 weeks. Do not freeze after reconstitution.
Quality Assurance
- Shipped to a ≥98% supplier batch specification
- Selected lots are independently tested by Janoshik Analytical
- Independent reports searchable by batch code at certapeptides.com/verify
- EU-based quality control under CERTALAB S.R.L.
Important Notice — Research Use Only
BPC-157 is supplied by CertaPeptides strictly as a laboratory research compound. The findings cited above are taken from preclinical, animal-model, and in vitro studies and are reported here for research context only. They are not medical claims. BPC-157 is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for use in humans or animals. It is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. For laboratory research purposes only. Not for human consumption.
Specification Summary
About BPC-157
What Is BPC-157?
BPC-157 ("Body Protection Compound 157") is a synthetic pentadecapeptide — a 15-amino-acid sequence originally isolated as a fragment of a protein found in gastric juice. It is supplied by CertaPeptides as a pharmaceutical-grade lyophilized powder for in vitro and preclinical research use.
CAS: 137525-51-0. Sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
What Published Research Has Reported
The statements below are direct attributions to peer-reviewed preclinical studies. They describe observations in animal models or in vitro systems only and should not be interpreted as human clinical claims.
- Sikiric et al. (2014) reviewed the role of the nitric oxide system in rodent BPC-157 studies and reported interactions between the pentadecapeptide and NO-pathway modulators in gastrointestinal and vascular experimental models. Source: Current Pharmaceutical Design, 20(7), 1126–1135. PMID 23755725.
- Chang et al. (2014) reported that, in cultured rat Achilles tendon fibroblasts, BPC-157 exposure was associated with increased growth hormone receptor expression compared to control. Source: Molecules, 19(11), 19066–19077. PMID 25415472.
- Krivic et al. (2008) observed, in a rat Achilles tendon-to-bone transection model, differences in early functional recovery measurements between BPC-157-treated animals and controls. Source: Inflammation Research, 57(5), 205–210. PMID 18594781.
- Staresinic et al. (2006) reported outcome measurements after application of BPC-157 in a rat transected-quadriceps model. Source: Journal of Orthopaedic Research, 24(5), 1109–1117. PMID 16609979.
Research Areas Where BPC-157 Is Studied
- Preclinical models of musculoskeletal tissue response (rodent tendon, ligament, muscle)
- In vitro fibroblast and endothelial cell culture assays
- Experimental gastrointestinal mucosa models in rats and mice
- Nitric-oxide pathway signalling studies in animal tissue
Within the Tissue-Repair Cluster — How BPC-157 Differs
BPC-157 is studied alongside two other research peptides in overlapping tissue-repair contexts: TB-500 (a 17-amino-acid fragment of thymosin β-4) and the combined BPC-157 + TB-500 blend. These compounds come from different biological origins and modulate different molecular pathways, which is why researchers often use them in combination rather than as substitutes:
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Biological origin | Fragment of a protein found in gastric juice (BPRP) | Active fragment (aa 17–23) of thymosin β-4, found in most mammalian cells |
| Amino acid length | 15 (pentadecapeptide) | 17 (heptadecapeptide) |
| Molecular weight | 1419.53 Da | 4963.5 Da |
| Primary mechanism studied | Nitric-oxide pathway, VEGFR2/angiogenesis, mucosal protection | Actin sequestration, cell migration, cytoskeletal dynamics |
| Best-characterised preclinical models | Rodent GI mucosa; Achilles/quadriceps transection; vascular NO assays | Cardiac epicardial progenitor; corneal inflammation; wound migration |
| Oral-route research context | Studied in oral delivery; shows gastric stability | Primarily injectable research; limited oral data |
BPC-157's distinguishing research angle is its gastric origin and mucosal-protection phenotype: it is the only compound in this cluster with published preclinical evidence in GI mucosa models, and the only one routinely studied under oral administration. For researchers investigating combined actin-cytoskeletal + nitric-oxide pathways in the same protocol, the BPC-157 + TB-500 blend presents a fixed 1:1 formulation; for independent dose control or single-pathway studies, the individual products are preferred. Researchers comparing the two frequently reference the TB-500 vs BPC-157 comparison, the blend-vs-individual decision guide, and the ultimate guide to BPC-157 research.
Specifications
| CAS Number | 137525-51-0 |
| Sequence | Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Molecular Formula | C62H98N16O22 |
| Molecular Weight | 1419.53 g/mol |
| Purity | ≥98% (supplier batch spec) |
| Physical Form | Lyophilized (freeze-dried) powder |
| Salt form | Acetate (standard BPC-157, not arginate/PDA) |
| Available Sizes | 2mg, 5mg, 10mg, 20mg |
Storage
Lyophilized: −20°C for long-term storage (2+ years stable). 2–8°C for short-term use.
Reconstituted: 2–8°C, use within 4 weeks. Do not freeze after reconstitution.
Quality Assurance
- Shipped to a ≥98% supplier batch specification
- Selected lots are independently tested by Janoshik Analytical
- Independent reports searchable by batch code at certapeptides.com/verify
- EU-based quality control under CERTALAB S.R.L.
Important Notice — Research Use Only
BPC-157 is supplied by CertaPeptides strictly as a laboratory research compound. The findings cited above are taken from preclinical, animal-model, and in vitro studies and are reported here for research context only. They are not medical claims. BPC-157 is not a drug, not a dietary supplement, not a cosmetic, and not approved by the FDA, EMA, or any other regulatory authority for use in humans or animals. It is not intended to diagnose, treat, cure, prevent, or mitigate any disease or condition. For laboratory research purposes only. Not for human consumption.
What research shows
Selected peer-reviewed studies from the published literature. Each describes laboratory or preclinical findings and is attributed to the cited study, not to this product. For research use only — not medical guidance.
Tendon and ligament repair
In cell-culture research on rat tendon fibroblasts, pentadecapeptide BPC 157 was reported to upregulate growth hormone receptor expression, a pathway the study links to fibroblast proliferation.
Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (2014). PMID: 25415472Skeletal muscle healing
In a rat model of corticosteroid-impaired healing, BPC 157 was associated with improved recovery of injured skeletal muscle.
Impact of pentadecapeptide BPC 157 on muscle healing impaired by systemic corticosteroid application. Medical Science Monitor (2010). PMID: 20190676Gastrointestinal anastomosis
In rat models, BPC 157 was associated with improved healing of esophagogastric anastomoses in laboratory studies.
Esophagogastric anastomosis in rats: Improved healing by BPC 157 and L-arginine, aggravated by L-NAME. World Journal of Gastroenterology (2016). PMID: 27895400Citations are provided for research reference. CertaPeptides (CERTALAB S.R.L.) is a reseller, not a manufacturer, and makes no medical, therapeutic, or efficacy claims. Products are for laboratory research use only and are not for human or animal consumption.
Related research reading
Objective comparisons and research guides covering this compound. Reference material for research use only.
Researcher Confidence
Why researchers choose CertaPeptides
Who actually tests this?
Selected lots are independently verified by Janoshik Analytical (Czech Republic) and published on the Janoshik public portal. Other lots ship with the supplier's batch specification. See /coa for the published wall.
View COAs →What if I get the wrong batch?
Every bottle label carries a lot number that maps to a specific Certificate of Analysis. If a batch fails spec, we don't ship it — full stop.
View COAs →Where does it ship from?
Romania (EU). We are CERTALAB SRL, CUI 54169956, VAT-registered. Sameday for Romania, GLS for most EU destinations, TCE Worldwide for the remaining cross-border EU and non-EU markets (UK, Switzerland, Iceland, Serbia). Delivery 1–15 business days depending on destination — exact window shown at checkout.
Shipping details →What if there's a problem?
You have a 14-day withdrawal right under OUG 34/2014 (Romanian/EU consumer law), with ANPC/ODR escalation available. Contact us at support@certapeptides.com.
Returns policy →Product Information
This product is intended for scientific research and development purposes only. It is a chemical substance that shall not be used as a drug, medicine, active substance, or ingredient in any product intended for human or animal consumption. Researchers must handle this compound in accordance with their institutional biosafety guidelines. Use only in properly equipped laboratory settings with appropriate personal protective equipment.
Frequently Asked
Related Research Articles
Researchers also explore related blends
Researchers studying BPC-157 also explore the fixed-ratio multi-peptide blends your supplier offers, each supplied as a single vial. Provided for laboratory research use only.
BPC-157 + TB-500 Blend
From €71.99
Glow Blend (BPC-157 + GHK-Cu + TB-500) 70mg
€101.99
